Johnson & Johnson's Phase 2b JASMINE Study Of Nipocalimab In SLE Meets Primary Endpoint
(RTTNews) - Johnson & Johnson (JNJ) on Tuesday reported positive topline results from the Phase 2b JASMINE study of nipocalimab in adults with systemic lupus erythematosus (SLE).
The study met its primary endpoint, with a statistically significant proportion of patients achieving the SLE Responder Index (SRI-4) composite response at Week 24 compared with placebo. Nipocalimab's safety and tolerability were consistent with previous Phase 2 studies, with no new safety signals identified.
Based on these results, J&J said it plans to initiate a Phase 3 program for nipocalimab in SLE.
On Monday, JNJ shares closed at $204.31, down 1.47%.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.